Search results
Apr 11, 2022 · CheckMate 816 builds on robust findings for nivolumab-based regimens in advanced NSCLC 12-14 and a strong biologic rationale for use in resectable NSCLC, especially in the neoadjuvant context....
- Osimertinib in Resected Egfr-Mutated Non–Small-Cell Lung Cancer
A total of 682 patients underwent randomization (339 to the...
- Neoadjuvant Pd-1 Blockade in Resectable Lung Cancer
Effective therapies are needed for patients with early-stage...
- Osimertinib in Resected Egfr-Mutated Non–Small-Cell Lung Cancer
Jun 5, 2024 · Neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with resectable NSCLC: 4-year update from CheckMate 816. LBA8010Background: The phase 3 CheckMate 816 study established neoadjuvant NIVO + chemo as a standard of care for eligible pts with resectable NSCLC.
May 15, 2024 · The clinical benefit of this regimen in patients with resectable NSCLC was initially observed in several phase 2 trials 1-3 and subsequently confirmed in the landmark phase 3 CheckMate 816 trial,...
May 26, 2022 · The addition of nivolumab to neoadjuvant chemotherapy did not increase the incidence of adverse events or impede the feasibility of surgery. (Funded by Bristol Myers Squibb; CheckMate 816 ClinicalTrials.gov number, NCT02998528.).
May 30, 2017 · These data provided the rationale for Checkmate 816 (NCT02998528), a phase 3 study evaluating nivo + ipi vs platinum-doublet chemotherapy as neoadjuvant treatment for early-stage NSCLC.
May 31, 2023 · Background: In CheckMate 816, neoadjuvant N + C demonstrated statistically significant and clinically meaningful improvements in event-free survival (EFS) and pathologic complete response (pCR) vs C in pts with resectable NSCLC.
Nov 1, 2023 · Neoadjuvant nivolumab plus chemotherapy significantly improved event-free survival (EFS) and pathologic complete response (pCR) versus chemotherapy alone in patients with resectable non-small-cell lung cancer (NSCLC) in the global phase III CheckMate 816 study.
